Pulling SEC filings + quote and writing the call…

Alignment Healthcare, Inc.
Next earnings Jul 28, 2026 (after close) · consensus $0.13 EPS, $1.34B rev
Last earnings +3.8% on 2026-04-30
Fast-growing Medicare Advantage disruptor just reached breakeven with strong cash flow and only 6% share — scaling story turning real.
Revenue $3.95B · FY2025
Alignment Healthcare is a technology-enabled, clinically focused Medicare Advantage insurer for seniors, pairing its AVA data platform with an employed Care Anywhere clinical model. The growth is exceptional and the profitability inflection is the key development: FY2025 revenue grew 46.1% to $3.95B, and after years of losses (-$128M as recently as FY2024), the company reached essentially breakeven net income (-$724K) with positive operating income of $14.8M and, most importantly, operating cash flow that turned strongly positive at $140M (+302%). Membership reached 236,300 (a 30% CAGR since inception) across 45 markets and five states.
The runway is large and the quality signals are strong. Management notes Alignment holds only ~6% market share of MA enrollees in its markets (with 10-30% share in its most mature markets), and 100% of its members are in plans rated 4 stars and above — the California HMO has held 4+ stars for nine consecutive years, which drives favorable CMS rebate economics. The balance sheet carries $576M cash and modest long-term debt ($323M); the 4.94x liabilities/equity ratio largely reflects insurance medical-claims reserves rather than financial leverage.
AI-generated analysis, produced by our proprietary engine from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jun 21, 2026, 4:58 PM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
Is ALHC a buy? The one-page verdict, explained →
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $1.17B | $1.43B | $1.82B | $2.70B | $3.95B |
| Gross profit | — | — | — | — | — |
| Operating income | -$178M | -$129M | -$128M | -$102M | $14.8M |
| Net income | -$195M | -$150M | -$148M | -$128M | -$724K |
| Diluted EPS | -$1.14 | -$0.83 | -$0.79 | -$0.67 | $0.00 |
| Net margin | -16.7% | -10.4% | -8.1% | -4.7% | -0.0% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Sources: SEC EDGAR (CIK 0001832466, latest 10-Q filed 2026-04-30) · EODHD · Proprietary analysis · as of 6/21/2026, 8:58:09 PM.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.
Last 90 days: 0 open-market buys · 8 sales
| 2026-07-01 | Hochradel Shane J. Chief Operations Officer | Award | 87.7K | |
| 2026-07-01 | KONOWIECKI JOSEPH S EVP, Corporate Affairs | Sell | 25.0K @ $24.00 | $600K |
| 2026-06-26 | KONOWIECKI JOSEPH S EVP, Corporate Affairs | Sell | 25.0K @ $23.00 | $575K |
| 2026-06-18 | KONOWIECKI JOSEPH S EVP, Corporate Affairs | Sell | 25.0K @ $22.00 | $550K |
| 2026-06-15 | Maroney Dawn Christine President | Sell | 30.0K @ $19.55 | $586K |
| 2026-06-12 | Kim Hyong Chief Medical Officer | Sell | 36.0K @ $19.86 | $714K |
| 2026-06-11 | KONOWIECKI JOSEPH S EVP, Corporate Affairs | Sell | 25.0K @ $21.00 | $525K |
| 2026-06-10 | KAO JOHN E Chief Executive Officer | Sell | 74.9K @ $19.65 | $1.47M |
| 2026-06-10 | KAO JOHN E Chief Executive Officer | Sell | 223K @ $20.60 | $4.59M |
Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.
1194 tracked peers · median
Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.